All tyrosine kinase inhibitor-resistant chronic myelogenous cells are highly sensitive to Ponatinib

The advent of tyrosine kinase inhibitor (TKI) therapy has considerably improved the survival of patients suffering chronic myelogenous leukemia (CML). Indeed, inhibition of BCR-ABL by imatinib, dasatinib or nilotinib triggers durable responses in most patients suffering from this disease. Moreover,...

詳細記述

保存先:
書誌詳細
主要な著者: Cassuto, Ophélie, Dufies, Maeva, Jacquel, Arnaud, Robert, Guillaume, Ginet, Clémence, Dubois, Alix, Hamouda, Amine, Puissant, Alexandre, Luciano, Fredéric, Karsenti, Jean-Michel, Legros, Laurence, Cassuto, Jill Patrice, Lenain, Pascal, Auberger, Patrick
フォーマット: Artigo
言語:Inglês
出版事項: Impact Journals LLC 2012
主題:
Research Papers
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC3681494/
https://ncbi.nlm.nih.gov/pubmed/23238683
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料